Much of the world’s data was generated in the past two years – 90% of it, in fact – which means that the majority of insights used by life science companies are new. And in two years, there will be even more data to contend with. How can pharmaceutical companies hope to keep up, and how can they turn data proliferation to their advantage?
We are rapidly seeing an evolution of the healthcare landscape, where accurate insights are becoming the bedrock for pharma to fulfill its obligations to patients. As such, the tech ecosystem pharma companies and medical affairs teams use to harness the data is crucial to performance. If managed properly, this data can unlock medical affairs’ ability to secure new strategic ground for their organizations.
But medical affairs teams often face barriers in using this data, even if they have access to it. Instead of working to their full capability, they struggle to engage the range of stakeholders they’d like to, forcing old routines back to the fore. Even if teams successfully engage stakeholders, the ability to turn those insights into action isn’t straightforward, and often teams become frustrated above all else.
In an upcoming talk at Reuters Pharma Europe, Within3 CEO Lance Hill will speak directly to these frustrations. The discussion will focus on:
- How a robust, data-led insights management strategy can help pharma companies get on top of their growing sets of data
- How to streamline and analyze the data to stay ahead of the competition
- How insights management technology can give companies a better understanding of disease communities
- How to identify and overcome the insights gap in your organization
Register to attend the Reuters Pharma Europe event and be part of the conversation around industry innovation.
